Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Infection. 2024 Aug;52(4):1527-1538. doi: 10.1007/s15010-024-02284-z. Epub 2024 May 10.
We aimed to improve the prognosis, treatment, and management of Staphylococcus aureus bacteremia (SAB) by evaluating the association between adherence to quality indicators (QIs) and clinical outcomes in patients with their clinical outcomes.
We retrospectively collected clinical and microbiological data on hospitalized patients with SAB from 14 hospitals (three with > 600, two with 401-600, five with 201-400, and four with ≤ 200 beds) in Japan from January to December 2022. The SAB management quality was evaluated using the SAB-QI score (ranging from 0 to 13 points), which consists of 13 QIs (grouped into five categories) based on previous literature.
Of the 4,448 positive blood culture episodes, 289 patients with SAB (6.5%) were enrolled. The SAB-QI scores ranged from 3 to 13, with a median score of 9 points. The SAB-QI score was highest in middle-sized hospitals with 401-600 beds. Adherence to each of the four QI categories (blood culture, echocardiography, source control, and antibiotic treatment) was significantly higher in survived cases than in fatal cases. Kaplan-Meier curves with log-rank tests demonstrated that higher adherence to SAB-QIs indicated a better prognosis. Logistic regression analysis revealed that age, methicillin resistance, multiple comorbidities (≥ 2), and low SAB-QI score were significantly associated with 30-day mortality in patients with SAB.
Our study highlights that greater adherence to the SAB-QIs correlates with improved patient outcomes. Management of patients with SAB should follow these recommended indicators to maintain the quality of care, especially for patients with poor prognosticators.
我们旨在通过评估金黄色葡萄球菌菌血症(SAB)患者的临床结局与临床结局之间的关系,改善 SAB 的预后、治疗和管理。
我们回顾性收集了 2022 年 1 月至 12 月期间来自日本 14 家医院(3 家医院的住院患者 SAB 的临床和微生物学数据,床位数超过 600 张,2 家医院 401-600 张,5 家医院 201-400 张,4 家医院床位数≤200 张)。使用 SAB-QI 评分(范围为 0 至 13 分)评估 SAB 管理质量,该评分基于先前的文献由 13 个 QI(分为五类)组成。
在 4448 次阳性血培养中,有 289 例患者患有 SAB(6.5%)入选。SAB-QI 评分范围为 3 至 13 分,中位数为 9 分。401-600 张床的中型医院的 SAB-QI 评分最高。存活病例的四项 QI 类别(血培养、超声心动图、源头控制和抗生素治疗)的依从性均显著高于死亡病例。对数秩检验的 Kaplan-Meier 曲线表明,较高的 SAB-QI 依从性与更好的预后相关。Logistic 回归分析显示,年龄、耐甲氧西林、多种合并症(≥2 种)和较低的 SAB-QI 评分与 SAB 患者的 30 天死亡率显著相关。
我们的研究表明,更高的 SAB-QI 依从性与改善患者结局相关。SAB 患者的管理应遵循这些推荐的指标,以保持护理质量,特别是对预后不良的患者。